Inhibition of Interleukin-4 Signalling in the Treatment of Atopic Dermatitis and Allergic Asthma
Open Access
- 30 June 2017
- journal article
- Published by Peertechz Publications Private Limited in Global Journal of Allergy
- Vol. 3 (1), 019-021
- https://doi.org/10.17352/2455-8141.000019
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Commonality of the IL-4/IL-13 pathway in atopic diseasesExpert Review of Clinical Immunology, 2017
- Dupilumab in the treatment of moderate-to-severe atopic dermatitisExpert Review of Clinical Immunology, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisThe New England Journal of Medicine, 2016
- Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL‐4Rα, in Atopic Dermatitis Patients and Normal VolunteersCPT: Pharmacometrics & Systems Pharmacology, 2016
- Dupilumab for the treatment of atopic dermatitis: A clinical trial reviewExpert Opinion on Biological Therapy, 2015
- Dupilumab: a novel treatment for asthmaJournal of Asthma and Allergy, 2014
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisThe New England Journal of Medicine, 2014
- Vitamins in the Therapy of Inflammatory and Oxidative DiseasesPublished by Bentham Science Publishers Ltd. ,2013
- The regulation of immunoglobulin E class-switch recombinationNature Reviews Immunology, 2003